AI assistant
IMUGENE LIMITED — Capital/Financing Update 2020
Aug 6, 2020
65124_rns_2020-08-06_abcf6cc9-75a6-4226-9ae9-5aee61de9412.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [116 x 42] intentionally omitted <==
7 August 2020 Imugene, Limited Level 3/62 Lygon Street Carlton Vic 3053
RE: IMUOA options exerciseable at 0.026
Dear IMU Option Share Holders,
We want to thank you for your continued support.
The listed IMUOA options exerciseable at $0.026 per option are currently in the money with IMU shares having closed at $0.059 (which is more than double the exercise price) on 31-July, 2020. We want to remind you that the expiry date for the IMUOA options is on 30th of November, 2020, being the last date to exercise these options.
All eligible shareholders will receive in the mail an IMUOA option conversion letter in due course. However if you want to convert all or part of your IMUOA options now, please call our Share Registry Automic on 1300 288 664 and provide your name (that the options are listed under), address and your HIN number. You will then be sent your option conversion form.
On a personal note, I have made a substantial investment in IMU by exercising 27 millon options which I hold, at a cost of $405,000.
In the past 12 months your company has experienced significant change and growth as evidenced by the acquisition of an important oncolytic virus program from the City of Hope Cancer Centre (COH) in Los Angeles. We completed a successful capital raise of $26 million and have seen a strong increase in share market capitalization. PD1-Vaxx, our B-cell check point inhibiting vaccine is in advanced stages of planning for a Phase 1 clinical study in lung cancer and we expect to dose patients in Australia and obtain an FDA IND before Christmas. HER-Vaxx, our Phase 2 gastric cancer vaccine continues to recruit patients to the study across centres in Eastern Europe and India. Progress reports will be made to shareholders as data becomes available.
==> picture [478 x 225] intentionally omitted <==
Sincerely,
Leslie Chong CEO/MD Imugene Limited
IMUGENE LIMITED Level 3, 62 Lygon Street, Carlton, VIC, 3053, AUSTRALIA